Marc Frahm
Stock Analyst at TD Cowen
(0.14)
# 4,290
Out of 4,918 analysts
14
Total ratings
16.67%
Success rate
-27.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SANA Sana Biotechnology | Upgrades: Buy | n/a | $3.91 | - | 2 | Jan 8, 2025 | |
| TBPH Theravance Biopharma | Maintains: Hold | $10 → $9 | $10.91 | -17.51% | 3 | Aug 6, 2024 | |
| INCY Incyte | Maintains: Buy | $88 → $80 | $75.59 | +5.83% | 3 | May 1, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $7.68 | - | 1 | Jun 15, 2023 | |
| XLO Xilio Therapeutics | Initiates: Outperform | n/a | $0.65 | - | 1 | Nov 16, 2021 | |
| NUVL Nuvalent | Initiates: Outperform | n/a | $77.76 | - | 1 | Aug 23, 2021 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $23.57 | - | 1 | Jul 6, 2021 | |
| DAWN Day One Biopharmaceuticals | Initiates: Outperform | n/a | $6.65 | - | 1 | Jun 21, 2021 | |
| BDTX Black Diamond Therapeutics | Initiates: Outperform | n/a | $2.59 | - | 1 | Feb 24, 2020 |
Sana Biotechnology
Jan 8, 2025
Upgrades: Buy
Price Target: n/a
Current: $3.91
Upside: -
Theravance Biopharma
Aug 6, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $10.91
Upside: -17.51%
Incyte
May 1, 2024
Maintains: Buy
Price Target: $88 → $80
Current: $75.59
Upside: +5.83%
Cullinan Therapeutics
Jun 15, 2023
Initiates: Outperform
Price Target: n/a
Current: $7.68
Upside: -
Xilio Therapeutics
Nov 16, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.65
Upside: -
Nuvalent
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $77.76
Upside: -
Janux Therapeutics
Jul 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $23.57
Upside: -
Day One Biopharmaceuticals
Jun 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.65
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.59
Upside: -